retatrutide treatment duration clinical trials New Phase 3 data just dropped 👀 Eli Lilly's trial reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Retatrutide for weight loss: Study

Not a long-term protocol

Despite strong efficacy, systemic barriers like coverage gaps and high out-of-pocket costs, especially for obesity indications, continue to drive abandonment

Basaglar carries approximately 25% hypoglycemia risk, while Ozempic has less than 1% risk

Different from the monoclonal antibody C5 inhibitor, zilucoplan, as a peptide, can be used with intravenous immunoglobulin and plasma exchange at the same time without supplementary administration, which is a new type of peptide drug with extremely simple administration

(A Ro spokesperson told me that any patient who receives a GLP-1 prescription through Ro has been determined to be clinically eligible for that treatment by a licensed medical provider.) But experts are divided over whether GLP-1s have the potential to improve athleticism